Herombopag Olamine in the Treatment of Thrombocytopenia After Chemotherapy
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of hetrombopag in the treatment of thrombocytopenia after
chemotherapy in patients with digestive system malignant tumors